Search Videos and More
Symposium
2026 American Society of Clinical Oncology (ASCO) Annual Meeting
Review scientific discoveries and information presented by Dana-Farber physician-scientists at the 2026 ASCO Annual Meeting in Chicago, IL, May 29 - June 2, 2026.
Symposium
2026 American Association for Cancer Research
Review scientific findings and information presented by Dana-Farber physician-scientists at the 2026 AACR Annual Meeting in San Diego, CA, April 17-22, 2026
News
ADC Provides Patients with Better Results Even After Subsequent Therapy for Advanced Triple-Negative Breast Cancer
A shift in the way advanced triple-negative breast cancer is treated may be on the horizon with mounting evidence that moving sacituzumab govitecan, an antibody-drug conjugate (ADC), to the first line of treatment confers long-term benefit compared to standard therapy, including continued benefit even after subsequent therapy.
News
Dana-Farber Research News 06.01.2026
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from May 1 - 15.
News
Perioperative Apalutamide in High-Risk Localized or Locally Advanced Prostate Cancer Reduces Risk of Metastasis and Death
High-risk localized and locally advanced prostate cancer patients treated with apalutamide — a next generation neoadjuvant androgen-receptor pathway inhibitor (ARPI) — plus hormone therapy before and after prostate cancer surgery resulted in more major pathologic responses and reduced the risk of metastasis or death, meeting both primary endpoints, in an international phase 3 clinical trial led by principal investigator Mary-Ellen Taplin, MD, medical oncologist at Dana-Farber Cancer Institute, and Adam Kibel, MD, chair of the Department of Urology at Mass General Brigham.
News
RAS(ON) Inhibitor Doubles Median Overall Survival in Results of Phase 3 Trial for Patients with Metastatic Pancreatic Cancer
At the ASCO annual meeting, Dana-Farber’s Brian Wolpin, MD, MPH, presented positive results from the RASolute 302 trial showing a substantial prolongation of survival for patients with previously treated metastatic pancreatic cancer, regardless of RAS mutation status, taking daraxonrasib, an investigational oral RAS(ON) multi-selective inhibitor, compared with chemotherapy.
News
Addition of Mezigdomide to Standard Therapy Significantly Improves Outcomes in Relapsed Refractory Multiple Myeloma
For patients with relapsed or refractory multiple myeloma (RRMM), the addition of the oral drug mezigdomide to standard treatment with carfilzomib and dexamethasone markedly improved progression-free survival over standard treatment alone, according to results from a phase 3 clinical trial led by investigators at Dana-Farber Cancer Institute.
News
Dana-Farber Researchers to Present Two Plenary Studies and Additional Late-Breaking Cancer Research at 2026 ASCO
Dana-Farber Cancer Institute researchers will present findings at the 2026 Annual Meeting of the American Society of Clinical Oncology (ASCO) from several studies with compelling and potentially practice-changing results spanning multiple cancer types, including pancreatic, prostate, breast, and multiple myeloma.
News
Dana-Farber Research News 05.15.2026
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from April 16 - 30.
News
Dana-Farber Study Finds Stage IV Breast Cancer Increasing in Incidence and Proportion Over the Last Decade
A new study from Dana-Farber Cancer Institute shows that cases of stage IV breast cancer, a common but largely difficult to treat disease, are increasing both in incidence and as a proportion of all breast cancer diagnoses. According to the findings, published today JAMA Network Open, the incidence rate of stage IV breast cancer has increased significantly, from 9.5 cases per 100,000 women in 2010 to 11.2 cases per 100,000 women in 2021. Stage IV, or de novo metastatic breast cancer, refers to cancer has already spread to distant organs at the time initial diagnosis.
Course
Early Detection and Interception of Cancer: Current Practice Recommendations and Novel Emerging Approaches
Elevate your approach to cancer prevention with this dynamic course offering practical guidance on current screening practices, management of high-risk populations, and the integration of emerging early detection technologies into clinical care.
News
RAS(ON) Inhibitor Daraxonrasib Shows Promising Results in Advanced Pancreatic Cancer Phase 1/2 Study
The targeted RAS inhibitor daraxonrasib was found to be safe and showed signs of efficacy in a phase 1/2 first-in-human trial in patients with previously treated, RAS-mutant, metastatic pancreatic cancer, according to a clinical trial led at Dana-Farber Cancer Institute and across the country.